High-Intensity Interval Training (HIIT) has become a prominent exercise modality known for its efficiency and effectiveness in improving various health outcomes. This review critically examines the positive and negative health aspects of HIIT, focusing on its impact on cardiovascular health, metabolic function, weight management, psychological well-being, and life expectancy. Evidence suggests that HIIT significantly enhances cardiovascular health by improving VO2 max, reducing blood pressure, and enhancing endothelial function. Metabolically, HIIT improves insulin sensitivity, glucose metabolism, and lipid profiles, while effectively reducing visceral fat and enhancing mitochondrial function. In terms of weight management, HIIT promotes fat loss and muscle maintenance, contributing to favorable body composition. Psychologically, HIIT has been shown to reduce symptoms of anxiety and depression, improve cognitive function, and enhance overall mental health. It has also a positive effect on chronic pain conditions. Emerging studies indicate that HIIT may reduce mortality risk and extend life expectancy by improving cardiovascular and metabolic health. Despite these benefits, HIIT also presents risks such as a higher incidence of musculoskeletal injuries, potential adverse cardiac events in high-risk individuals, and the risk of overtraining and burnout. Special populations, including older adults, children, adolescents, and individuals with chronic conditions, can benefit from HIIT, but modifications and precautions are necessary to ensure safety and effectiveness. The review underscores the importance of individualized HIIT program design, thorough assessment, and continuous monitoring to maximize benefits while minimizing risks. Future research should focus on long-term effects, optimal protocols for diverse populations, and personalized HIIT approaches to enhance safety and efficacy.

In this narrative review, we investigate the essential role played by the computed tomography Aortic Valve Calcium Score (AVCS) in the cardiovascular diagnostic landscape, with a special focus on its implications for clinical practice and scientific research. Calcific aortic valve stenosis is the most prevalent type of aortic stenosis (AS) in industrialized countries, and due to the aging population, its prevalence is increasing. While transthoracic echocardiography (TTE) remains the gold standard, AVCS stands out as an essential complementary tool in evaluating patients with AS. The advantage of AVCS is its independence from flow; this allows for a more precise evaluation of patients with discordant findings in TTE. Further clinical applications of AVCS include in the assessment of patients before transcatheter aortic valve replacement (TAVR), as it helps in predicting outcomes and provides prognostic information post-TAVR. Additionally, we describe different AVCS thresholds regarding gender and the anatomical variations of the aortic valve. Finally, we discuss various scientific studies where AVCS was applied. As AVCS has some limitations, due to the pathophysiologies of AS extending beyond calcification and gender differences, scientists strive to validate contrast-enhanced AVCS. Furthermore, research on developing radiation-free methods of measuring calcium content is ongoing.

Surgeries and procedures in otolaryngology require close collaboration between anesthesiologists and ENT specialists, especially for operations involving the larynx and airways, which pose challenges for maintaining airway patency and visibility. Choosing the type of anesthesia, whether general or local, is crucial. This study examines the benefits and drawbacks of both types of anesthesia in tonsillectomy and adenoidectomy, tympanostomy and myringotomy, and flexible endoscopic biopsy of the pharynx and larynx. A review of current guidelines, systematic reviews and relevant clinical cohort studies was conducted. The findings highlight several advantages of local anesthesia, including shorter operation times, reduced hospital stays, lower costs, decreased use of analgesics, and improved patient comfort.

Aims: This study aims to evaluate the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, in promoting weight loss in patients with obesity. Methods: A comprehensive literature review was conducted using PubMed and Google Scholar databases for articles published between 2020 and 2024. Keywords included tirzepatide, LY3298176, tirzepatide obesity, tirzepatide side effects, and tirzepatide adverse effects. Studies included were randomized, placebo-controlled, and involved patients with a body mass index (BMI) ≥ 30 kg/m² or ≥ 27 kg/m² with at least one weight-related comorbidity. Results: Analysis covered 5,385 participants from phase 2 and 3 trials, with 3,517 treated with tirzepatide and 1,868 receiving placebo. Tirzepatide demonstrated significant weight reduction across studies: SURMOUNT-1 (15.0%, 19.5%, 20.9% weight loss for 5, 10, 15 mg doses respectively), SURMOUNT-2 (12.8%, 14.7% for 10, 15 mg doses), NASH SYNERGY (10.7%, 13.3%, 15.6% for 5, 10, 15 mg doses), and SURMOUNT-OSA (17.7%, 19.6% for maximum tolerated dose). Adverse effects were mostly gastrointestinal, with nausea, diarrhea, and vomiting being the most common, leading to a discontinuation rate of 4.6%. Conclusions: Tirzepatide demonstrates superior efficacy in weight management compared to existing treatments, with an acceptable safety profile. Its dual agonist action offers a promising therapeutic option for obesity, warranting further research into its long-term benefits and impacts on obesity-related comorbidities.

Purpose of Research: This study aims to evaluate the impact of various artificial sweeteners on gut microbiota and their potential health implications. Research Materials and Methods: A literature review was conducted using PubMed, focusing on keywords such as gut microbiota, artificial sweeteners, non-nutritive sweeteners, and intestinal microbiota. The review includes descriptions of sweeteners like aspartame, sucralose, saccharin, acesulfame K, and stevia, as well as their metabolism and effects on the human body. Primary Results: Artificial sweeteners can disrupt gut microbiota balance, reducing beneficial bacteria like Bifidobacterium and Lactobacillus while increasing pathogenic bacteria such as Clostridium difficile and E. coli. Clinical trials show mixed results, with some studies indicating significant changes in microbiota composition and diversity, while others show no substantial effects. Differences influence the variability in study outcomes in participants' initial microbiota composition, lifestyle, and dietary habits. Conclusions: Artificial sweeteners impact gut microbiota, but the extent and nature of these effects still need to be fully understood. Further standardized, long-term research is required to clarify these effects and determine whether the benefits of artificial sweeteners outweigh potential risks to gut health. Advanced research methods like metagenomics and next-generation sequencing will enhance our understanding of artificial sweeteners' interaction with gut microbiota, aiding in comprehensive health assessments.

Congenital adrenal steroidogenesis disorders are rare diseases that can lead to life-threatening conditions in newborns, primarily salt-wasting syndrome and adrenal crisis. It is therefore essential for paediatricians and family physicians to be familiar with the symptoms suggestive of steroidogenesis defects, such as failure to thrive, vomiting, dehydration, electrolyte imbalances, and abnormal appearance of external genitalia. Early initiation of diagnostic procedures enables the prompt introduction of appropriate hormonal replacement therapy. However, the diagnostic process is not straightforward and requires consideration of other rare causes of the disease, which often present with similar but diverse clinical, biochemical, and hormonal features. A normal result of a screening test assessing 17-hydroxyprogesterone levels does not rule out rare causes of steroidogenesis disorders, which should be considered in the differential diagnosis when the aforementioned symptoms are present. This report discusses three newborns: one diagnosed with congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, and two with aldosterone synthase deficiency.